KRAS and non-small cell lung carcinoma: Therefore, to clarify the impact of somatic mutations on RFS and OS for resected NSCLC, the follow up data and clinical outcomes of the JME study were collected prospectively, and the impact of somatic mutations, including EGFR, KRAS, and TP53 and coexisting multiple mutations, on RFS and OS was analyzed.